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Abstract
The ACTA2 gene encodes for smooth muscle specific α-actin, a critical component of the contractile apparatus of
the vascular smooth muscle cell. Pathogenic variants in the ACTA2 gene are the most frequently encountered
genetic cause of non-syndromic hereditary thoracic aortic disease (HTAD). Although thoracic aortic aneurysm and/
or dissection is the main clinical manifestation, a variety of occlusive vascular disease and extravascular
manifestations occur in ACTA2-related vasculopathy. Current data suggest possible mutation-specific manifestations
of vascular and extra-aortic traits.
Despite its relatively high prevalence, comprehensive recommendations on the care of patients and families with
pathogenic variants in ACTA2 have not yet been established. We aimed to develop a consensus document to
provide medical guidance for health care professionals involved in the diagnosis and treatment of patients and
relatives with pathogenic variants in ACTA2.
The HTAD Working Group of the European Reference Network for Rare Vascular Diseases (VASCERN) convened to
review current literature and discuss expert opinions on clinical management of ACTA2 related vasculopathy. This
consensus statement summarizes our recommendations on diagnosis, monitoring, treatment, pregnancy, genetic
counselling and testing in patients with ACTA2-related vasculopathy. However, there is a clear need for additional
prospective multicenter studies to further define proper guidelines.
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Background
Thoracic aortic aneurysm/dissection (TAAD) represents
a vascular condition with life-threatening complications,
including aortic dissection or rupture. Depending on the
presence or absence of manifestations in other organ
systems, TAAD can be subdivided into syndromic and
non-syndromic. Heritable thoracic aortic disease
(HTAD) refers to thoracic aortic disease caused by a
pathogenic variant in a gene that confers a high risk for
TAAD.
The ACTA2 gene (OMIM #102620, ORPHA 91387,
2573, 404,463) encodes for smooth muscle cell specific
isoform of alpha-actin. Pathogenic variants in the gene
are the most frequently encountered cause of non-
syndromic HTAD with detection rates varying between
1,5–21%, probably depending on the inclusion criteria of
the screened population [1–11].
ACTA2-related vasculopathy is an autosomal domin-
ant condition with aortic aneurysm and risk of dissection
as main vascular phenotype, and occasional extravascu-
lar traits such as skin (i.e. livedo reticularis) and ocular
abnormalities (i.e. iris flocculi). The penetrance of the
vascular phenotype is incomplete and age-related: ac-
cording to the limited data available thus far, children
usually do not manifest aortic dilatation/aneurysm. Thus
far, some case reports and one comprehensive series
comprising 277 ACTA2 mutation carriers have been re-
ported; the main findings are listed in Table 1 [1, 3, 6,
12–15].
Multisystem smooth muscle dysfunction syndrome
(MSMD syndrome, OMIM #613834, ORPHA 404463) is
a severe phenotype caused by de novo pathogenic vari-
ants affecting the Arg179 residue of the ACTA2 gene
and is characterized by aortic and cerebrovascular dis-
ease, fixed mydriatic pupils, hypotonic bladder, intestinal
hypoperistalsis, pulmonary hypertension and white mat-
ter brain anomalies [16–23]. Specific management rec-
ommendations have been suggested for MSMD
syndrome patients and therefore MSMD is not included
in these recommendations [24].
This consensus statement focuses on the diagnosis, moni-
toring and treatment of patient with ACTA2-related vascu-
lopathy including genetic counselling. This document
represents a disease-specific, preliminary recommendation
that certainly will require adjustment and expansion of con-
tents as scientific and clinical insight evolves.
Methods
The international ACTA2 consensus group comprised
21 participants from 15 institutions in 9 countries with a
shared interest in improving the care for patients with
ACTA2 mutations. All participants (apart from two co-
operating guests) are members of the Heritable Thoracic
Aortic Disease (HTAD) working group of the European
Reference Network on rare vascular diseases (VAS-
CERN), and includes cardiologists, cardiac surgeons and
clinical geneticists and all are experts of the disease for
having diagnosed, monitored and treated more than 65
families together. The aim of the working group was to
develop consensus recommendations in order to
standardize and optimize the care for patients and fam-
ilies with pathogenic variants in the ACTA2 gene.
Our group evaluated the relevant literature to formu-
late recommendations. An inventory of nine questions
on the most debatable ACTA2-related topics was sent to
all members of the working group. (Additional file 1:
Table S1) The inventory and its recommendations were
then discussed at two plenary sessions and one video
conference call held between September 2017 and May
2018 and were used to formulate the following European
recommendations on ACTA2-related vasculopathy. The
consensus document was approved by all members of
the working group.
Results
Existing international literature on patients with a patho-
genic variant in the ACTA2 gene are often too general
with regard to screening recommendations. The results
Table 1 ACTA2 clinical features
Main clinical manifestation based on refs [1, 3, 6, 12–15]
– most frequent presenting feature: acute aortic dissection
– Stanford type A dissection more common (54% @ median age
36 yrs) than type B (21% @ median age 27 yrs)
– 15–57% @ aortic diameter < 5 cm (often in peri-partum period)
– Age dependent occurrence of aortic dissection
○ Rare/absent in children
○ Cumulative risk for aortic event (aortic dissection or surgical
aneurysm repair) @85y: 76%
– aortic events more prevalent in males (62%) than in females
(38%); p = 0.003
– Risk aortic event higher with pathogenic variants affecting the
Arg179 and Arg258 residue, lower with p.(Arg185Gln) and
p.(Arg118Gln) pathogenic variants
– 6% of pregnancies complicated by aortic dissection (third trimester
of shortly after delivery)
Other clinical features
– Occlusive vascular disease
○ Premature coronary artery disease (youngest @28 yrs)
○ Moya-Moya like cerebrovascular disease – more common with
pathogenic variant affecting the Arg258 residue
– Congenital Heart Disease
○ Persistent ductus arteriosus (10%)
○ Bicuspid aortic valve (4%)
○ Atrial septal defect
– Iris Flocculi (iris cysts at the pupillary border) – more common with
p.(Arg149Cys) variant
– Livedo reticularis
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are constituted of recommendations with regard to
screening, monitoring, treatment, life-style advices, pre-
conception and pregnancy management for patients with
a pathogenic variant in ACTA2 (excluding MSDM pa-
tients). In addition, recommendations with regard to
genetic counselling and testing of index patients and
their families are composed.
Diagnosis and monitoring
At initial diagnosis, we recommend 2D-transthoracic
echocardiography (2D-TTE) and complete vascular im-
aging of thorax and abdomen (neck to pelvis) from the
age of 18 years. Imaging has to be performed according
to established guidelines for each corresponding
technique and obtained values have to be corrected for
age, BSA and gender. 2D-TTE is the method of choice
in the assessment and follow-up of the aortic root and
proximal ascending aorta diameters [25, 26]. Measure-
ments are obtained from the parasternal long axis view
at end-diastole according to the leading-edge to leading-
edge convention. CT and MRI provide information of
the entire aorta and peripheral vessels [27]. CT has the
best special resolution but low-dose electrocardiographi-
cally gated protocols should be used to decrease radi-
ation exposure. MRI has significant advantages in the
follow-up of patients with genetic disorders adding func-
tional information to anatomical data without the bur-
den of ionizing radiation. Aortic root measurement is
performed by SSFP cine sequence images and the rest of
the aorta by 3D-angiogram. Multiplanar reconstruction
of the axial source data can create aortic images in a
plane perpendicular to the aortic lumen direction
(double-oblique or true short-axis images of the aorta)
by CT and MRI. There is general consensus that in both
imaging techniques the aortic diameter should be mea-
sured with the inner-to-inner convention at end-
diastole.
With an aneurysm of the ascending aorta we recom-
mend 2D-TTE with a time schedule based on the indi-
vidual characteristics of the patient (age, sex) and the
TAA (diameter, growth, shape). With an aneurysm in
another artery or in the distal part of the aorta, imaging
is recommended yearly, the technique depending on the
location of the aneurysm. If no aneurysm is found, en-
largement of the ascending aorta is monitored by yearly
2D-TTE of the aortic root and the ascending aorta only.
We recommend complete imaging of the vascular tree
from neck to pelvis once every two to 5 years (Fig. 1). In
children, we recommend yearly 2D-TTE from the age of
diagnosis, although intervals can be extended depending
on clinical judgement. With normal diameters on echo-
cardiography, computerised tomography angiography
(CTA)/magnetic resonance angiography (MRA) imaging
of the thoracoabdominal aorta is recommended at the
age of 18 years (Fig. 1). The choice for CTA or MRA de-
pends on local expertise and availability, always aiming
to keep radiation exposure as low as possible.
No systematic imaging of the cerebral vessels is rec-
ommended since there is at present insufficient data to
make recommendations for treatment. In patients with
symptoms potentially related to cerebral vasculopathy,
we recommend imaging according to local guidance and
clinical review by Neurology and/or Neurosurgery ser-
vices. Imaging of the coronary arteries should be limited
to patients with symptoms suggesting ischemic heart
disease and in patients scheduled for elective aortic
surgery.
Ophthalmological examination for detection of iris
flocculi is recommended at diagnosis and in patients
with symptoms. In young children, the ophthalmological
examination can be postponed until they can more easily
comply.
Treatment of aortic aneurysm
Elective aortic root replacement should be considered
in asymptomatic patients with a maximal aortic diam-
eter between 45 and 50 mm. The American Heart As-
sociation (AHA) recommends a threshold of 45 mm
[28] and there is currently no European Society of
Cardiology (ESC) recommendation for this topic.
Since no additional data have become available, there
is no consensus on the threshold. The indications for
preventive surgery should consider risk factors such
as rate of aortic growth, aortic valve dysfunction,
body surface area, family history of aortic dissection,
and hypertension. Women planning a pregnancy
should be considered for preventive surgery at aortic
diameters ≥45 mm (see pregnancy section). For elect-
ive intervention, we recommend valve sparing aortic
root replacement according to David reimplantation
technique of valve sparing root replacement when
feasible and in the absence of surgical contraindica-
tions such as leaflet fenestrations or relevant aortic
valve regurgitation. External aortic support proce-
dures, offered in a limited number of centres, has no
established role in this population.
Elective replacement of the descending thoracic
aorta should be performed according to the ESC,
AHA and European Society for Thoraco Vascular
Surgery (ESTVS) guidelines [28–30]. Operative deci-
sions are often difficult and therefore the benefits and
risks should be a matter of collective discussion of
the patient with the vascular surgeons. There is, at
present, no consensus on appropriateness or indica-
tions for endovascular procedures in ACTA2 aortopa-
thy. The general rule is to avoid endoprostheses in
patients with genetic aortopathies [29].
Laar et al. Orphanet Journal of Rare Diseases          (2019) 14:264 Page 3 of 7
Treatment of aortic dissection
Type A aortic dissection always requires immediate sur-
gical intervention whether or not a pathogenic ACTA2
variant is present. Valve sparing aortic root replacement
should also be considered in this and the risk of coron-
ary artery dissection should be taken into account.
Type B aortic dissections require initial medical man-
agement and surgery in case of complications as in pa-
tients without ACTA2 mutations [12]. Endovascular
therapy should be avoided in the presence of genetic
aortopathies [29].
Medical treatment
Scientific proof for medical benefit in patients treated
with β-blockers is not available. Medications that reduce
hemodynamic stress, such as β-blockers, should be con-
sidered in ACTA2 patients, with aortic dilatation (aortic
diameter at z-score ≥ 2) or hypertension or progression
of aortic dilatation (> 0,3 cm/year) and is reasonable to
propose in ACTA2 patients without dilatation. The use
of other antihypertensive drugs can be discussed with
the treating clinician.
Hypertension should be treated according to the
ESC hypertension guidelines which state that all
hypertensive patients with aortic dilatation, should
have their blood pressure controlled ≤130/80 mmHg
[31]. Patients with a pathogenic variant in ACTA2
should be managed according to standard strategies
for other cardiovascular risk factors, including dyslip-
idemia [28, 29].
Fig. 1 Summary of the screening and management of patients with pathogenic ACTA2 variants
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Lifestyle
Patients should be advised to avoid smoking and sub-
stance abuse as for all patients. Endurance sports can be
of great value to control body weight, blood pressure
and fitness. In patients with aortic dilatation/aneurysm,
we recommend low static, dynamic sports such as swim-
ming, walking, running and cycling, without competitive
spirit. The physical activity level, both in children and
adults, should be adjusted by the cardiologist based on
the evaluation of aortic dimensions and valvular func-
tion. However, we recommend the avoidance of sports
with abrupt isometric or static manoeuvers or any other
activities with significant increase in arterial blood pres-
sure, such as weightlifting, competitive football, basket-
ball, handball, and tennis.
Preconception
For preconception care we recommend counselling of all
carriers by a pregnancy heart team with cardiologist (spe-
cialized in preconception care), obstetrician, and clinical
geneticist for evaluation of the aortic risk, counselling of
the risks for the future mother, father and children, in-
cluding discussion of invasive prenatal diagnostic testing
and pre-implantation genetic diagnostics [32]. Imaging of
the entire aorta is recommended prior to pregnancy.
Women who have a medical history of aortic dissection
should be advised not to become pregnant. Women with
aortic root diameters ≥45mm should be advised to
undergo prophylactic aortic root replacement prior to
pregnancy. Teratogenic drugs (e.g. angiotensin receptor
blockers such as losartan and irbesartan) should be dis-
continued – β-blockers should be considered throughout
pregnancy (preferably metoprolol or labetalol).
Pregnancy management
Foetal surveillance
If the genetic status of the foetus is unknown or the
foetus carries an ACTA2 mutation, standardized cardiac
ultrasound of the foetus around a gestational age of 20
weeks should be offered due to the slightly increased risk
of congenital heart malformations. Many congenital
heart malformations associated with ACTA2 mutations
might however be difficult to detect prenatally on ultra-
sound (e.g. patent ductus, bicuspid valve) [3, 12]. Regular
foetal growth monitoring should also be performed in
pregnant women who are taking β-blockers because of
the associated small risk of foetal growth retardation.
Maternal surveillance
Since little data on pregnancies in ACTA2 mutation
carriers are available, we recommend management in
pregnant women as for pregnant women with Marfan
syndrome [32].
Monitoring (2D-TTE) of the aortic diameter of the
pregnant woman with ascending aortic pathology every
4–12 weeks (depending on the severity of dilatation)
throughout the pregnancy and 6months post-partum is
recommended.
Delivery
In low risk pregnancies (aortic diameter < 40 mm or Z-
score < 2 without growth, no aortic dissections in family)
the indications and decision for vaginal delivery in hos-
pital should be discussed with the patient who should be
aware that, although rare, the risk of dissection during
or after delivery may also occur at an aortic diameter
lower or around 40 mm [13, 14].
Moderate and high risk pregnancies should be man-
aged by a cardiac and obstetric team with experience in
managing patients with aortopathies in an expert center
with the option of acute cardiothoracic surgery support.
In patients with moderate risk (ascending aortic diameter
40-45mm), vaginal delivery should be carefully considered
on an individual basis. Vaginal delivery should be assisted
with expedited second-stage and regional anaesthesia. In
high-risk pregnancies (ascending aortic diameter > 45
mm) caesarean delivery should be considered [32].
Genetic counselling and genetic testing
Genetic counselling should be systematically offered to
all patients carrying (or at risk for carrying) a pathogenic
variant in ACTA2. The counselling aims to collect infor-
mation and clinical reports of family members, and to
inform the consultants of the possible genetic origin of
their disease. The genetic work-up should include review
with a clinical geneticist who will assess for traits that
can potentially recur in patients with ACTA2-related
vasculopathy as well as other, previously unreported
traits. Clinical annotation is fundamental for expanding
and collecting observations that may complete the list of
the traits of the disease (either markers or abnormalities
deserving care).
Cascade genetic testing should be offered in families
with probands harbouring pathogenic variants in
ACTA2. In the case of variants of unknown significance
(VUS), in particular novel missense variants, clinical
family screening is recommended. Segregation studies in
families are essential especially when functional studies
are not available or are not feasible.
Each family member that accepts counselling and
testing should give his/her informed consent. The
counselling process provides the opportunity for
informing and discussing current knowledge and data
on potential disease-specific risks, and the benefits of
genetic testing in order to facilitate autonomous
decision-making. Studies of psychological implication
of genetic testing for other cardiovascular diseases
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have shown that the genetic risk is perceived to be
manageable {Oliveri, [33] #47}.
Predictive genetic testing of minors is generally ac-
cepted for childhood-onset conditions, if preventative or
therapeutic measures are available to reduce morbidity
or mortality. Although there is no scientific proof for
medical benefit in children treated with β-blockers, we
advise to propose treatment from the age of 4 years as
stated above. Therefore the inclusion of children in the
family genetic testing program appears beneficial. The
genetic test to evaluate for the ACTA2 mutation identi-
fied in the proband of the family can be performed in
the paediatric age using a saliva sample, to avoid the dis-
comfort of blood sampling. In particular, when genetic
testing is performed in children under the age of 16 we
strongly recommend proper genetic counselling involv-
ing psychosocial support.
Conclusions
Patients affected by ACTA2-related vasculopathy will
usually be diagnosed due to an incidental detection of
aortic dilatation, or after an acute dissection. Coronary
or cerebrovascular disease should be assessed in symp-
tomatic patients. Monitoring programs should be tai-
lored to each single patient. Medications such as β-
blockers can be considered with the major aim to reduce
haemodynamic stress in the aorta. Patients should be
carefully screened and monitored for arterial hyperten-
sion and treated in order to fully control blood pressure.
Preventive aortic surgery should be considered based on
general indications, individual needs and risk factors.
Since ACTA2-related vasculopathy is a recently de-
scribed condition, the phenotypic spectrum and precise
risk factors are probably not fully understood. It is there-
fore essential to follow these patients at tertiary refer-
ence centres, and subsequently report recurring features
of the disease. This would enrich the clinical character-
isation and facilitate the suspect, thus addressing pa-
tients and families to referral centres.
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